Dongjin Semichem: Profit Recovery in H1 2026 and a 21.7% One-Month Share Price Rise

Thesis

The data supports a picture of improving profitability. Trailing net income of ₩209.1B is more than double the ₩99.1B reported for 2025, and trailing ROE of 18.8% compares with 9.5% for 2025. Trailing revenue of ₩1.12T is below the 2025 level of ₩1.19T and well below 2024's ₩1.41T, so the profit recovery has not come with a revenue recovery. Trailing net income also exceeds operating income, which suggests non-operating gains contributed. The data does not show the source. The shares are 31.2% below the 52-week high of ₩72,200 and 57.6% above the low of ₩31,500. The one-month gain of 21.7% is large against a one-year return of 6.0%. Foreign ownership, investor flows and short balance data are not available, so we cannot say who has been buying.

Business overview

Dongjin Semichem is a KOSDAQ-listed company in the chemicals sector. It was founded on 1973-07-10 and listed on 1999-12-21. It has 51,414,494 listed shares and a market capitalization of about ₩2.55T. Revenue was ₩1.16T in 2021, peaked at ₩1.46T in 2022, fell to ₩1.31T in 2023, rose to ₩1.41T in 2024 and fell 15.2% to ₩1.19T in 2025. The data gives no segment or product breakdown, so we cannot describe what drives these swings.

Financial analysis

All figures come from filed financial statements (DART). Operating income was ₩131.8B in 2021, ₩216.3B in 2022, ₩176.2B in 2023, ₩208.2B in 2024 and ₩172.4B in 2025. Operating margin ranged between 11.4% and 14.8% over 2021-2025 and reached 16.5% on a trailing basis as of H1 2026. Net margin on the same basis is 18.6%. Annual net income was ₩154.8B in 2024 and ₩99.1B in 2025, and ROE fell from 17.2% to 9.5% over that period. Trailing ROE of 18.8% is above 2022's 25.5%? No, it is below it, and in line with the 17.0-18.7% seen in 2021, 2023 and 2024. On the balance sheet, cash is ₩411.6B against borrowings of ₩168.3B, and liabilities to equity is 81.6%. Trailing free cash flow is ₩148.6B.

Valuation

Current multiples are a P/E of 12.2, P/B of 2.1, P/S of 2.3, EV/EBITDA of 9.2 and a dividend yield of 1.3%. Enterprise value is about ₩2.31T. At year-end 2025 the P/E was 19.0 and the P/B was 1.7, so the P/E is lower now because earnings rose, while the P/B is higher. Year-end multiples for earlier years are not available. Among the listed peers, Hanwha has a P/E of 10.3 and KCC 1.1, while LG Chem, Hanwha Solutions and SKC show no P/E. Peer P/B ratios range from 0.4 to 1.8, all below Dongjin's 2.1. The peers are much larger in market capitalization except SKC at ₩3.65T, so comparability is limited.

Catalysts

• The half-year report filed on 2026-08-14 and the preliminary earnings of 2026-08-06 are the latest results showing the margin improvement.
• A buyback trust contract was signed on 2026-07-31, but the trust was cancelled by a filing on 2026-08-31 with a result report on 2026-09-02, so the data does not show how many shares were bought.
• IR events on 2026-05-21 and 2026-08-24 show ongoing investor communication, though the data gives no content.
• Several 5%+ holding reports were filed between 2026-05-04 and 2026-06-08, which point to changes in large shareholdings, though the data gives no details.
• The next quarterly report will show whether the trailing margin of 16.5% holds.

Risks

• Revenue has fallen from ₩1.41T in 2024 to a trailing ₩1.12T, so profit gains rest on margins rather than sales growth.
• Trailing net income above operating income suggests non-operating items may be inflating earnings, and the data does not identify them.
• The share price rose 21.7% in one month, and the P/B of 2.1 is above the year-end 2025 level of 1.7.
• Annual revenue growth has swung between -15.2% and +25.5%, showing volatile results.
• Investor flow, foreign ownership, short interest and news data are unavailable, which limits insight into market positioning.

Closing view

The filed numbers show a clear improvement in margins and returns in H1 2026, a solid balance sheet with cash above borrowings, and positive free cash flow. Against that, revenue remains below recent years, earnings may include non-operating items, and the share price has already risen sharply over the past month. Valuation on earnings is lower than at the end of 2025, but the book multiple is higher and peer comparisons are patchy. The evidence is mixed and incomplete, and the missing flow and news data leave important questions open.

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Report history

1. Oct 13, 2026InitiationDongjin Semichem: Profit Recovery in H1 2026 and a 21.7% One-Month Share Price Rise